Citius Oncology (CTOR) vs ProMIS Neurosciences (PMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ProMIS Neurosciences (PMN) has outperformed Citius Oncology (CTOR) over the past year, losing 32.4% versus a loss of 54.7%. Citius Oncology is the larger company by market cap ($90.9 million vs $83.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTOR | PMN |
|---|---|---|
| Share price | $0.8598 | $9.28 |
| Market cap | $90.93M | $83.19M |
| 1-day change | +0.44% | +1.72% |
| YTD return | -14.90% | +33.53% |
| 1-year return | -54.73% | -32.44% |
| 5-year return | — | -95.95% |
| EPS (TTM) | $-0.48 | $-11.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.25 | $27.40 |
| 52-week low | $0.491 | $6.27 |
| Distance from 52-week high | -61.79% | -66.14% |
| Average volume | 99.72K | 84.01K |
| Shares outstanding | 105.76M | 8.97M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PMN has outperformed CTOR by 22.3 percentage points over the past year.
CTOR vs PMN FAQ
Which is bigger, Citius Oncology or ProMIS Neurosciences?
Citius Oncology (CTOR) is larger, with a market capitalization of $90.93M compared with $83.19M for ProMIS Neurosciences (PMN).
Which stock has performed better over the past year, CTOR or PMN?
PMN returned -32.44% over the past 12 months, compared with -54.73% for CTOR (price return, excluding dividends). Past performance does not predict future results.
Are Citius Oncology and ProMIS Neurosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.